{"cdcTestId":"2021-0027","testcaseName":"Dose #2 of Pfizer Covid-19 Vaccine at 21 - 5 days (age 12 years) before ACIP instituted minimum interval","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on age","assessmentDate":"2021-10-26T00:00:00","patient":{"dob":"2009-02-01T00:00:00","gender":"M"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2021-10-06T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2021-10-22T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"3","earliestDate":"2022-03-22T00:00:00","recommendedDate":"2022-03-22T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2021-10-06T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2021-10-22T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T10:11:15.283","generalDescription":"This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21 - 5 days after the first dose, and before ACIP instituted a minimum interval on 10/25/2021, that the dose is valid. A booster dose should be forecast.","changedInVersion":"4.27","reasonForChange":"v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). \nv4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).\nv4.14 Updated the test case to show that the status of the series is complete. Per ACIP guidance, no boosters are recommended for any patient under 18 years of age."}